Dose-Dependent efficacy and safety of Brexpiprazole in agitation associated with dementia in Alzheimer’s disease: A systematic review and meta-analysis

Key Points

• Brexpiprazole shows notable efficacy for reducing agitation in patients with dementia, indicating significant effects at various dosage levels.
• The analysis includes data from multiple studies, reflecting a diverse population of Alzheimer's patients and identifying trends in treatment outcomes.
• This systematic review and meta-analysis highlight key findings related to both the safety and efficacy of using brexpiprazole for agitation in Alzheimer’s disease.
• Further research is needed to solidify findings and explore long-term effects of brexpiprazole in dementia management.